Plaquenil is a brand-name medication that contains hydroxychloroquine as its active ingredient. Hydroxychloroquine belongs to a class of drugs known as antimalarials, which are also used to modulate the immune system in certain autoimmune disorders. In Hong Kong, Plaquenil is a prescription-only product (approved by the Department of Health) and is available in tablet form at strengths of 200 mg and 400 mg.
Hydroxychloroquine exerts several pharmacologic actions that are relevant to its therapeutic uses:
After oral administration, hydroxychloroquine is well absorbed. Its onset of action in autoimmune diseases can take several weeks, whereas antiparasitic effects begin within a few days. The drug has a long elimination half-life (approximately 40-50 days), which contributes to its once-daily dosing schedules.
Plaquenil is FDA- and EMA-approved for the following indications, which are also recognized by Hong Kong health authorities:
These approved uses are based on clinical trials demonstrating efficacy in reducing disease activity scores and preventing malaria infection after travel to endemic regions.
Hydroxychloroquine has been investigated as a potential treatment or preventive agent for COVID-19. Large, well-controlled randomized trials have not confirmed a clear benefit, and major health agencies (e.g., WHO, FDA) consider its use for COVID-19 to be not approved. Off-label prescription for this purpose should only occur under close medical supervision, with acknowledgment of the limited efficacy data and possible safety concerns.
Research continues to explore hydroxychloroquine in diseases such as certain dermatologic conditions (e.g., cutaneous lupus) and as an adjunct in oncologic protocols. These investigations remain experimental; the medication is not formally approved for these purposes.
If any of these conditions apply, a healthcare professional should evaluate suitability before initiating therapy.
Most of these effects are reversible upon dose reduction or discontinuation.
Because interaction data are continually updated, patients should provide a complete medication list-including over-the-counter products and herbal supplements-to their prescriber.
The exact regimen should be individualized by a prescriber. Tablet splitting is acceptable for the 200 mg strength but not recommended for the 400 mg tablet unless the manufacturer indicates it is scored.
If a dose is missed and the next scheduled dose is more than 12 hours away, take the missed dose as soon as remembered. Do not double the dose to make up for a missed one.
Signs of acute overdose may include severe nausea, vomiting, visual disturbances, and cardiac arrhythmias. Seek emergency medical care immediately; supportive care and cardiac monitoring are the mainstays of treatment. No specific antidote exists.
Long-term therapy can be tapered gradually to minimize the risk of disease flare in autoimmune conditions. Abrupt cessation is discouraged without medical guidance.
Patients should report new visual symptoms (blurred vision, difficulty reading) or cardiac symptoms (palpitations, syncope) promptly.
This article provides educational information about Plaquenil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Current evidence from large randomized trials does not support hydroxychloroquine for COVID-19 prevention. Health authorities in Hong Kong and internationally consider this an off-label use that should only be undertaken within a clinical trial or under strict medical supervision.
Patients often notice a gradual reduction in disease activity over several weeks to months. Full therapeutic effect may require up to 6 months of consistent therapy.
Stop the medication and contact a healthcare professional promptly. A rash can be an early sign of hypersensitivity or a more serious skin reaction that requires medical assessment.
Hydroxychloroquine is sometimes continued during pregnancy for lupus or rheumatoid arthritis when the benefits outweigh potential risks. A specialist should evaluate each case individually.
Baseline eye testing is recommended before starting therapy, followed by a screening at six months, then annually thereafter, especially after five years of continuous use.
Most antihistamines do not interact with hydroxychloroquine. However, it is advisable to inform your pharmacist or doctor about all medications you are using.
Plaquenil is a branded formulation that contains the same active ingredient as generic hydroxychloroquine. Differences may exist in inactive fillers or tablet coating, which can affect tolerability for some patients.
Hydroxychloroquine can cause mild alterations in liver enzymes and blood counts. Your clinician may order periodic labs to monitor any changes.
The medication can increase photosensitivity in some individuals. Using sunscreen and protective clothing when outdoors is recommended.
Do not flush tablets down the toilet. Return unused medication to a pharmacy waste program or follow the Hong Kong Department of Health’s guidelines for safe disposal.
